Maciej Zieliński, Justyna Sakowska, Dorota Iwaszkiewicz-Grześ, Mateusz Gliwiński, Matylda Hennig, Magdalena Żalińska, Anna Wołoszyn-Durkiewicz, Anna Jaźwińska-Curyłło, Halla Kamińska, Radosław Owczuk, Wojciech Młynarski, Przemysława Jarosz-Chobot, Artur Bossowski, Agnieszka Szadkowska, Wojciech Fendler, Iwona Beń-Skowronek, Agata Chobot, Małgorzata Myśliwiec, Janusz Siebert, Natalia Marek-Trzonkowska, Piotr Trzonkowski
An imbalance between exaggerated autoaggressive T cell responses, primarily CD8 + T cells, and impaired tolerogenic mechanisms underlie the development of type 1 diabetes mellitus. Disease-modifying strategies, particularly immunotherapy focusing on FoxP3 + T regulatory cells (Treg), and B cells facilitating antigen presentation for T cells, show promise. Selective depletion of B cells may be achieved with an anti-CD20 monoclonal antibody (mAb). In a 2-year-long flow cytometry follow-up, involving 32 peripheral blood T and B cell markers across three trial arms (Treg + rituximab N = 12, Treg + placebo N = 13, control N = 11), we observed significant changes...
March 29, 2024: International Immunopharmacology